“Xybion is delighted to welcome Novo Nordisk to our client community; this opens yet another chapter in the Pristima history and is a further testament to the configurability that our engineers have built into the product.”
Morris Plains, N.J., October 1, 2015 /PRNewswire/ — Xybion Corporation announced today that Novo Nordisk (NYSE: NVO) has selected Xybion’s Pristima® Suite to manage all its non-GLP pharmacology studies in a global setting. The Pristima Suite is a preclinical software platform that offers a fully integrated, end-to-end enterprise solution for tracking and managing veterinary facilities and animal studies throughout the preclinical research process.
Xybion will provide a number of services and improvements to the Pristima platform to support non-GLP pharmacology studies, enabling Novo Nordisk to leverage the system for early drug discovery studies. In addition, Xybion will provide critical training and implementation services to configure Pristima and prepare the user community to meet Novo Nordisk best practices and reporting specifications.
Dr. Pradip Banerjee, CEO at Xybion stated, “Xybion is delighted to welcome Novo Nordisk to our client community; this opens yet another chapter in the Pristima history and is a further testament to the configurability that our engineers have built into the product. Our strategies facilitate scientists’ research activities, improve their efficiency and ensure the quality of their findings. I am excited that this project provides an for an additive set of functions targeted directly at the pharmacology teams of our pharmaceutical clients and further expands the integrative value that Xybion and Pristima bring to the market.”
Carlos Frade, VP of Preclinical R&D Solutions at Xybion commented, “After a diligent assessment in which Novo Nordisk and Xybion analyzed the approaches by which Pristima supports the operational planning, the data collection, the data evaluation, the instrument interfacing and efficiency improvements provided by Pristima, I am confident that we are delivering the best enterprise solution for drug discovery teams all over the world.”
Xybion is a leading provider of software, services and consulting for global corporations operating in highly regulated industries. Our unique solutions focus on integrated preclinical lab management, early-stage drug discovery, regulatory compliance, GRC, quality management and systems validation.
Xybion’s combination of software, business process management, services, validation and staffing enables us to cover a broad spectrum of critical business needs for companies and we deliver our solutions on global scale. Our leadership in this dynamic and ever-changing industry has been a cornerstone of our high-value reputation. To learn more, please visit www.xybion.com.
The Pristima® Suite is a fully integrated, end-to-end enterprise solution for tracking and managing veterinary facilities and research subjects throughout the preclinical research process. From ordering through the study submission process, the Pristima software platform delivers essential capabilities across the entire drug discovery process. The system enables organizations to maintain all preclinical data in one system, from compound receipt through dossier submission and slide archival. For over 35 years, global pharmaceutical companies and CROs have relied on Xybion to drive data management while ensuring quality, efficiency, and compliance.
609-512-5790 x 316
Head of Quality Assurance
Heidi leads Xybion’s Quality Assurance practice. She has over 20 years’ experience in designing and implementing quality assurance policies. Since joining Xybion in 2000, Heidi worked with several clients to design quality policies and ensure compliance. She is responsible to hosting Xybion customer audits. Heidi has a BA degree in Biology from The King’s College.